IO Biotech, Inc. financial data

Symbol
IOBT on Nasdaq
Industry
Pharmaceutical Preparations
Location
Ole Maaloes Veh 3, Copenhagen, Denmark
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.02K % -29%
Debt-to-equity 12 % +32.5%
Return On Equity -70.1 % -23.4%
Return On Assets -62.6 % -20.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.9M shares 0%
Common Stock, Shares, Outstanding 65.9M shares +129%
Entity Public Float 31.1M USD -57.5%
Common Stock, Value, Issued 66K USD +128%
Weighted Average Number of Shares Outstanding, Basic 65.9M shares +129%
Weighted Average Number of Shares Outstanding, Diluted 65.9M shares +129%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 69.6M USD +31.6%
General and Administrative Expense 23.8M USD +2.77%
Operating Income (Loss) -93.4M USD -22.8%
Nonoperating Income (Expense) 6.1M USD +49.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -87.3M USD -21.4%
Income Tax Expense (Benefit) 703K USD -65.6%
Net Income (Loss) Attributable to Parent -88M USD -19%
Earnings Per Share, Basic -1.26 USD/shares +51%
Earnings Per Share, Diluted -1.26 USD/shares +51%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 101M USD -8.49%
Assets, Current 108M USD -4.76%
Property, Plant and Equipment, Net 735K USD -11%
Operating Lease, Right-of-Use Asset 1.94M USD -23.6%
Other Assets, Noncurrent 876K USD -1.68%
Assets 111M USD -5.18%
Accounts Payable, Current 5.02M USD +12.4%
Employee-related Liabilities, Current 2.52M USD +33.1%
Liabilities, Current 13.7M USD +26.2%
Operating Lease, Liability, Noncurrent 1.47M USD -31.8%
Liabilities 15.2M USD +16.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -9.63M USD +1.42%
Retained Earnings (Accumulated Deficit) -304M USD -40.8%
Stockholders' Equity Attributable to Parent 96.3M USD -7.89%
Liabilities and Equity 111M USD -5.18%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.9M USD -69.7%
Net Cash Provided by (Used in) Investing Activities -11K USD +92.6%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 65.9M shares +129%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 151M USD +233%
Deferred Tax Assets, Valuation Allowance 57.9M USD +65.5%
Deferred Tax Assets, Gross 58.4M USD +64.2%
Depreciation 62K USD +31.9%
Payments to Acquire Property, Plant, and Equipment 11K USD -92.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -87.9M USD -16.8%
Lessee, Operating Lease, Liability, to be Paid 2.37M USD -24.9%
Operating Lease, Liability, Current 678K USD +10.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 791K USD +0.38%
Lessee, Operating Lease, Liability, to be Paid, Year One 785K USD -0.51%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 395K USD -50.3%
Deferred Tax Assets, Operating Loss Carryforwards 50.3M USD +60.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Operating Lease, Payments 193K USD +10.3%
Additional Paid in Capital 410M USD +24.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 250K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 479K USD -17.6%
Share-based Payment Arrangement, Expense 7.76M USD +2.4%
Interest Expense 302K USD -16.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%